Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

First International Summit on Interventional Pharmacoeconomics

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Jun

Today In Oncology

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Related Videos

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

FDA Approves Capivasertib Plus Abiraterone and Prednisone for Metastatic Prostate Cancer

AGA Recommends Colonoscopy Over Alternative Colorectal Cancer Screening Methods

AI-Assisted Tumor Volume Response Criteria Outperform Physician Assessments and RECIST Criteria in Pleural Mesothelioma

Overall Survival With EBRT in Hepatocellular Carcinoma

HCC TACE Plus STRIDE With or Without Lenvatinib